Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Gossamer Bio Announces Third Quarter 2019 Financial Results
November 12, 2019 4:05 PM ESTClinical programs on track for multiple topline data releases in 2020
Entered clinical trial collaboration with Merck to evaluate KEYTRUDA® (pembrolizumab) in combination with GB1275 in advanced solid tumors
Company to host conference call today at 4:30 p.m. ET
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical... More
